The Medical Advisor

In the U.S., 66% of adults are estimated to have at least one prescription, and the average person has nine filled annually (1). As an awake physician (2), one of the most depressing aspects of my work is seeing patients, especially the elderly, weighed down by numerous prescriptions that frequently do more harm than good. For example, as I showed here , statins provide a negligible benefit (e.g., at best, taking them for five years extends one’s lifespan by 3 to 4 days) but create significant side effects such as severe muscle pain and cognitive impairment for 20% of users. This tragic situation is best demonstrated by a 2007 study which showed that simply discontinuing the least necessary prescriptions resulted in a 23% reduction in the death rate and an 18.2% decrease in hospital referrals (3). Sadly, since the trend in medicine is always to have people on more drugs, data like this has had no effect on the practice of the overprescription of medications. Over the years,...

White Paper · Integrative Oncology · June 2026 ✎ OneDayMD Editorial Team  Last Updated: June 21, 2026   Medically Reviewed by: OneDayMD Editorial Team  DOI-equivalent: onedaymd.com/fenbendazole-cancer-protocol-2026 Abstract Background: Cancer remains the second leading cause of death globally. Advanced-stage disease carries poor prognosis, and a significant proportion of patients either fail conventional therapy or seek adjunctive options. Over the past decade, the repurposed antiparasitic agents fenbendazole, ivermectin, and mebendazole have attracted increasing attention for potential anti-neoplastic activity based on preclinical and emerging clinical data. Objective: To synthesise (1) a systematic case-series compilation of 760+ patient-reported outcomes across 31 cancer subtypes involving antiparasitic repurposed drugs; (2) an evidence-based 7-layer Metabolic Cancer Frame...